GC Green Cross to Establish Blood Product Factory in Indonesia

GC Green Cross announced on the 1st that it has received final approval from the Indonesian Ministry of Health and Welfare for the business rights related to the construction of a blood product plant and technology transfer within Indonesia.

GC Green Cross Ochang Plant Panorama [Photo by GC Green Cross]

The Indonesian government has been conducting a selection process for the business operator regarding the construction of the blood product plant and technology transfer. In January, GC Green Cross was selected as the preferred negotiator, and after detailed discussions and coordination, the official notification of business approval was recently received. The specific contract scale and details will be disclosed after the main contract is signed. GC Green Cross plans to proceed with the project aiming to start construction within this year.

Since the 1970s, GC Green Cross has been producing various blood products starting with albumin, and in 2009, it completed the Ochang plant, the largest blood product factory in Asia. Currently, it exports 12 items to 32 countries, actively continuing its blood product business.

It is also explained that GC Green Cross is the only company that has successfully completed the export of blood product plants not only domestically but also globally. It was the first domestic company to export a blood product plant to Thailand and has experience and know-how in constructing factories in various countries such as China and Canada. Through the blood product plant construction and technology transfer project, the Indonesian government plans to produce blood products using plasma from Indonesian citizens, which currently relies entirely on imports, thereby realizing stable localization of blood products.

A GC Green Cross official stated, “With this business rights approval, GC Green Cross’s high technological capabilities in the blood product field over half a century have been recognized globally once again,” adding, “In particular, it is significant that through cooperation in the bio-industry sector, our government and private companies have steadily worked together to win the business rights bid from a foreign government.”

Meanwhile, SK Plasma, a subsidiary of SK Discovery, is also promoting the construction of a blood product plant in Indonesia together with Daewoong Infion, a local joint venture of Daewoong Pharmaceutical. In March, they received final approval from the Indonesian Ministry of Health to build a blood product plant near Jakarta, Indonesia, and construction is currently underway. The facility is planned to be completed by mid-2025 and will be capable of processing 1 million liters of plasma raw material annually.